CYP2C19 Genotyping

The CYP2C19 gene codes for the CYP2C19 enzyme that plays a role in the processing of the anti-platelet drug Clopidogrel which is used to prevent blood clot formation. Multiple variations (polymorphisms) in the CYP2C19 gene have been associated with clopidogrel resistance, a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. The polymorphisms that are associated with clopidogrel resistance decrease the enzyme’s ability to convert the drug to its active form.

CYP2C19 genotyping is effective in determining a patient’s reactivity to Clopidogrel before starting a treatment regime.


CAP Accreditation : 9007683   
CLIA Accreditation : 34D2205781